Back to top

vaccines: Archive

Zacks Equity Research

MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot

Moderna jumps 4% after EU panel backs mCombriax, its COVID-19-flu combo shot, with phase III data showing stronger immune response vs standalone vaccines.

SNYPositive Net Change GSKNegative Net Change MRNANegative Net Change

Zacks Equity Research

Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates

NVAX stock jumps 17% after Q4 swings to a surprise profit on strong licensing revenues and lower costs, with sales soaring 67% year over year.

SNYPositive Net Change PFENegative Net Change NVAXNegative Net Change